Entospletinib, an oral SYK inhibitor, has completed phase Ib/II trial (NCT02343939) and showed favorable response rates when combined with induction chemotherapy in AML patients with KMT2A translocations, NPM1 mutations and FLT-3 ITD mutations all with a shared HOXA9/MEIS1 signature [67]. This evidence concerns the gene FLT3 and acute myeloid leukemia.